


Date: 23<sup>rd</sup> Sep 2025



## CURRICULUM VITAE

### PERSONAL INFORMATION

Faculty Member Name: Majdoleen Omar Alalawneh  
Academic Rank: Assistant Professor  
College: Pharmacy  
Department: Pharmacy  
Nationality: Jordanian  
Address: Amman – Shafa Badran  
Phone No: 00962781616217      0097477654300  
E-mail: m.alalawneh@aau.edu.jo

### ACADEMIC QUALIFICATIONS

Degrees with fields, institution, and date

- **B.S. in program, university, year:** Pharmacy, Jordan University of Science and Technology, 2002-2007
- **M.Sc. in program, university, year:** Pharmaceutical Sciences, Applied Science University, 2014-2017

**Theses title:** Syrian Refugees Crises in Jordan: The Impact of Medication Management Review Service

- **Ph.D. in program, university, year:** Pharmaceutical Sciences, Qatar University, 2019-2024

**Dissertation title:** The Effect of Obesity on Rivaroxaban Pharmacokinetics and Pharmacodynamics

### ACADEMIC EXPERIENCE

- Duration: 4 years



دائرة الموارد البشرية  
**Human Resources Department**

- University: Qatar University
- Academic Rank: Teaching Assistant
- Date the rank was granted: 2019 - 2023
- The body granting the rank: Qatar University
- College: Pharmacy
- Country: Qatar

**NON-ACADEMIC EXPERIENCE**

- Duration: Pharmacist, Head Pharmacist, Teacher (Qatar and United Kingdom)
- Institution: AL-Shefa'a Pharmacy, Al-Deera Pharmacy, Next Generation School, Aberdeen School
- Department:
- Country: Jordan, Jordan, Qatar, United Kingdom

**CERTIFICATIONS OR PROFESSIONAL REGISTRATIONS**

- Clinical Research Associate Certification (80 hours), VIARES Academy, Jan 2025.
- GastroPlus Software Training Workshop (17 hours). Simulation Plus, PBPK modeling and simulations, Dec 2024
- CITI Hamad Medical Corporation Good Clinical Practice - Medical Research Center Reviewers (GCP), Sep 2024
- CITI Conflicts of Interest - Conflicts of Interest, Sep 2024
- CITI Hamad Medical Corporation Good Clinical Practice – Hamad Medical Corporation Clinical Trials Investigators (GCP), Jan 2021
- CITI Health Information Privacy and Security (HIPS), HMC Biomedical and Social Behavioral Researchers (HIPS), Jan 2021
- CITI Basic Introduction to Biosafety, Feb 2024
- Qatar University Summer Internship 2020 Program at Central Lab Unit, from 7 to 11 June, under title “Chromatographic Techniques: Fundamentals, Instrumentation and Application”.
- Basic Nursing Skills, 30 Hours Extensive Course at Jordan University for Science and Technology, 2006

**CURRENT MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS**



#### HONORS AND AWARDS

- Research Distinguishing Award for graduate students, Qatar University 2024
- 3-Minutes Thesis competition, 2nd place-PhD Program, Qatar University Health Cluster, 2023

#### SERVICE ACTIVITIES

- Media appearance '*Breaking New Ground in Rivaroxaban Research: Controlled Clinical Trial from Qatar University*', Qatar Television, Oct 2024. Available at: [حياتنا - الأحد 2024/10/20](#)

#### THE MOST IMPORTANT PUBLICATIONS IN LAST FIVE YEARS

- Journal Articles:
  1. **Alalawneh M**, Awaisu A, Abdallah I, Elewa H, et al. Pharmacokinetics of Single Dose Rivaroxaban under Fed State in Obese vs. Non-Obese Subjects: An Open-Label Controlled Clinical Trial (RIVOBESSE-PK). *Clinical and Translational Science*. **2024** May; 17(6): e13853
  2. **Alalawneh M**, Rachid O, Abdallah I, Mahfouz A, Elewa H, Danjuma MI, et al. Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data. *European Journal of Clinical Pharmacology*. **2023** Dec;79(12):1675-85.
  3. **Alalawneh M**, Berardi A, Nuaimi N, Basheti IA. Improving Syrian refugees' knowledge of medications and adherence following a randomized control trial assessing the effect of a medication management review service. *PloS one*. **2022**;17(10)
  4. **Alalawneh M**, Awaisu A, Rachid O. Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review. *Clinical Pharmacokinetics*. **2022**;61(12):1677-95.
  5. Mukhalalati BA, Ibrahim MMME, **Alalawneh MO**, Awaisu A, Bates I, Bader L. National assessment of pharmaceutical workforce and education using the International Pharmaceutical Federation's global development goals: a case study of Qatar. *Journal of Pharmaceutical Policy and Practice*. **2021**;14(1):1-18.

6. **Alawneh MA**, Nuaimi N, Abu-Gharbieh E, Basheti IA. A randomized control trial assessing the effect of a pharmaceutical care service on Syrian refugees' quality of life and anxiety. *Pharmacy Practice*. 2020;18(1).
  7. **M. Alalawneh**, N. Nuaimi, I.A. Basheti. Pharmacists in humanitarian crisis settings: Assessing the impact of pharmacist-delivered home medication management review service to Syrian refugees in Jordan. *Research in Social and administrative Pharmacy*, 10 (2018), pp. 30858-130856.
- Conferences and Poster Presentations:
    1. **Alalawneh M**, Awaisu Ahmed, Rachid O. Modeling and Simulation of Rivaroxaban Pharmacokinetics in a Virtual Obese Population Using Artificial Intelligence-Based Computational Methods. **AI and Medicine at Sidra, Qatar**. April 23<sup>rd</sup>-26<sup>th</sup> 2025, ID: 651461
    2. **Alalawneh M**, Awaisu Ahmed, Rachid O. Impact of obesity on rivaroxaban pharmacokinetics: a systematic review. **Pharmacy Education, Science, and Practice Conference**, at **Qatar**. April 17<sup>th</sup>-19<sup>th</sup> 2025. *Pharmacy Education, Science, and Practice Conference 2025 Supplement Part B*. (2025). *Pharmaceutical Development and Technology*, 30(sup1), S1–S21. <https://doi.org/10.1080/10837450.2025.2484517>, ID: 44
    3. **Alalawneh M**, Awaisu A, Abdallah I, Elewa H, et al. A controlled clinical trial of single-dose rivaroxaban in fed obese subjects: pharmacokinetic and pharmacodynamic findings from the RIVOBESSE-PK study. **Pharmacy Education, Science, and Practice Conference**, at **Qatar**. April 17<sup>th</sup>-19<sup>th</sup> 2025. *Pharmacy Education, Science, and Practice Conference 2025 Supplement Part B*. (2025). *Pharmaceutical Development and Technology*, 30(sup1), S1–S21. <https://doi.org/10.1080/10837450.2025.2484517>, ID: 53
    4. **Alalawneh M**, Rachid O, Abdallah I, Mahfouz A, Elewa H, Danjuma M, Mohamed A, Awaisu A. Trends in Prescribing and Outcomes in Obese versus Non-obese Patients Receiving Rivaroxaban Therapy: A Retrospective Observational Study Using Real-world Data. **Sixth Qatar International Pharmacy Conference**, at **Qatar**, November 3<sup>rd</sup> and 4<sup>th</sup> 2023, ID# QIPC-85

5. **Alalawneh M**, Abdallah I, Elewa H, Awaisu A, Rachid O. Pharmacokinetics and Pharmacodynamics of Rivaroxaban after a Single Dose under Fed State in Obese vs. Non-Obese Subjects: Open-Label Controlled Clinical Trial. **Sixth Qatar International Pharmacy Conference**, at **Qatar**, November 3<sup>rd</sup> and 4<sup>th</sup> **2023**, ID# QIPC-79
6. **Alalawneh M**, Abdallah I, Elewa H, Awaisu A, Rachid O. Pharmacokinetics of a Rivaroxaban Single Oral Dose under Fed State in Obese vs. Non-Obese Healthy Subjects: Open-Label Controlled Clinical Trial. **American College of Clinical Pharmacy (ACCP)**, at **USA**, May 23<sup>rd</sup>, **2023** Poster Symposium. presentation ID# 62209.
7. **Alalawneh M**, Awaisu A, Rachid O. The Effect of Obesity on Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban. **American Association for Pharmaceutical Sciences Conference (AAPS, PharmSci 360)** at **USA**, Oct. 26 – Nov. 5, **2020** (Poster). Poster reference 894245, AAPS ePoster Library. Alalawneh M. 10/25/20; 304892; 894245
8. **Alalawneh M**, Nuaimi N, Basheti IA. Syrian Refugees Crises in Jordan: The Impact of Medication Management Review Service. **ASU Pharmacy Third Conference of the Association of Faculties of Pharmacy at Jordanian University**, Jordan, April/2017

#### INSTITUTIONAL PROFESSIONAL DEVELOPMENT ACTIVITIES IN THE LAST FIVE YEARS

.....

#### RESEARCH LINK (Scopus and Google Scholar)

Google Scholar Profile:

<https://scholar.google.com/citations?user=S5Ui0m8AAAAJ&hl=en>

Research Gate: [Majdoleen Alalawneh](#)

LinkedIn: <https://www.linkedin.com/in/majdoleen-alalawneh-559981291/>

Scopus: <https://www.scopus.com/authid/detail.uri?authorId=57919399800>

#### LANGUAGES

- Arabic
- English